Skip to content
Open access

Applicability of Non‐Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study

Sep 2026 · Liver international (Print) · Vol 46 · 1 citation · 12 references
Medicine

TL;DR

This work aimed to quantify and compare real‐world treatment eligibility according to the AASLD and expert panel‐derived criteria and to evaluate classification of patients with available liver histology.

Abstract

Non‐invasive tests (NITs) are increasingly used to guide patient selection for pharmacological treatment of metabolic dysfunction‐associated steatohepatitis (MASH). We aimed to quantify and compare real‐world treatment eligibility according to the AASLD and expert panel‐derived criteria and to evaluate classification of patients with available liver histology.

Read PDF

Similar papers

Review Open access Sep 2026

Non‐Invasive Fibrosis Testing in Adults With Obesity and MASLD: A Systematic Review and Meta‐Analysis

Adults with obesity are at increased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD)‐related fibrosis, but the diagnostic performance of non‐invasive tests (NITs) in this population remains uncertain. This meta‐analysis evaluated NITs for detecting significant (≥F2) and advanced (≥F3) fibrosis...

Patricia M. Ortega, L. Sabatella, P. Manousou et al. · 0 citations
Review Open access Oct 2026

Systematic Review: Inclusion of Patients With Difficult‐to‐Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies

Criteria to define difficult‐to‐treat (DTT) inflammatory bowel disease (IBD) have recently been proposed, yet the inclusion and participation of patients with DTT‐IBD in randomized controlled trials (RCTs) are heterogeneous and poorly defined.

T. Parigi, V. Solitano, H. Mekonnen et al. · 0 citations
Open access Oct 2026

When Does Nonintensification Constitute Clinician Inertia? A Viewpoint on LAI-LCARE

Puri and colleagues report a nationwide assessment of lipid-lowering treatment among 9,658 Indian patients with coronary artery disease. 1 They document poor low-density lipoprotein cholesterol (LDL-C) goal attainment, low use of combination therapy

Shambo Samrat Samajdar, Shashank R. Joshi · 0 citations
Open access Oct 2026

Drug‐Induced Ductopenia in Two Prospective Registries: Favourable Outcomes and Late Recovery Despite Prolonged Cholestasis

Drug‐induced ductopenia (DID) represents a rare histological phenotype of drug‐induced liver injury (DILI), typically associated with prolonged cholestasis and historically linked to poor outcomes. This study aimed to characterize the clinical presentation, histological features and outcomes of DID using data from the...

F. Bessone, N. Hernández, M. Schinoni et al. · 0 citations
Open access Oct 2026

Prospective, Population‐Based Evaluation of Costs and Outcomes of Status Epilepticus According to the New Definition

To address the paucity of data on outcomes and costs of status epilepticus (SE) following the updated 2015 International League Against Epilepsy (ILAE) definition and changes in clinical practice guidelines in Germany.

C. Jünemann, Meike Menche, Jens-Peter Reese et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.